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Formulation and in vitro evaluation of niacinloaded nanoparticles to reduce prostaglandin
mediated vasodilatory flushing
D.L. COOPER, J.A. CARMICAL, P.C. PANUS, S. HARIRFOROOSH
Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State
University, Johnson City, TN, USA

Abstract. – OBJECTIVE: Niacin, activating
G-protein coupled receptor (GPR) 109A, stimulates release of vasodilatory prostaglandins
(PGs) such as PGE2 which can elicit niacin-associated flushing side effects. Poly-lactic-coglycolic acid (PLGA) and poly-lactic acid (PLA)
are used in nanoparticle (NP) drug delivery to
reduce adverse effects and modulate drug release. Our study evaluated the in vitro effects
of niacin-loaded PLGA or PLA-NPs on PGE2 expression in whole human blood as a model for
niacin-induced flushing.
MATERIALS AND METHODS: NPs were formulated using a solvent evaporation process
and characterized by size, polydispersity, zeta
potential, drug entrapment, morphology, and
drug release. NP in vitro effects on PGE 2 release were measured via ELISA analysis.
RESULTS: PLGA-NPs demonstrated the lowest NP size (66.7 ± 0.21 nm) with the highest zeta potential and percent drug entrapment (42.00
± 1.62 mV and 69.09 ± 0.29%, respectively)
when compared to PLA-NPs (130.4 ± 0.66 nm,
27.96 ± 0.18 mV, 69.63 ± 0.03 %, respectively). In
vitro release studies showed that PLGA-NPs
underwent significant reductions in cumulative
drug release when compared to PLA-NPs (p <
0.05). Furthermore, when compared to plain
niacin, PLGA-NPs significantly reduced in vitro
PGE2 release (p < 0.05).
CONCLUSIONS: These results support the
use of PLGA-NPs as a novel method of delivery
for reducing niacin-associated flushing.
Key Words:
Niacin, Nanoparticles, Prostaglandins, PLGA, PLA, Formulation, Flushing.

Introduction
Niacin, also known as nicotinic acid or vitamin B3 (Figure 1), has been shown to positively
regulate lipoprotein levels1. It is one of the few

compounds shown to significantly raise HDL
levels and regress atherosclerosis2,3. The effects
of niacin are thought to occur primarily through
interactions with the G-protein coupled receptor
(GPR)109A4-6. Physiologically, niacin functions
to alter lipoprotein levels through several mechanisms. In adipocytes, niacin can induce changes
in hormone sensitive lipase (HSL) and lipoprotein lipase (LPL) expression levels, in turn inhibiting lipolysis, reducing systemic free fatty
acid (FFA) release and subsequent lipoprotein
repackaging via hepatic triglyceride (TG) synthesis7. Niacin has also demonstrated an ability to
inhibit the enzyme responsible for hepatic de novo lipogenesis, diacylglycerol acyltransferase 2
(DGAT2)4. Inhibition of DGAT2 reduces hepatic
TG production, in turn altering production of TG
dependent lipoproteins such as very low density
lipoproteins (VLDL) and low density lipoproteins (LDL) making it a highly effective drug for
treatment of dyslipidemia.
Despite niacin’s beneficial effects on lipid regulation, certain adverse side effects are common.
The most prevalent adverse effect of niacin use is
cutaneous vasodilation, often presented as flushing of the face and extremities. Niacin interactions
at the GPR109A receptor can trigger intercellular
signaling pathways that increase the expression of
vasodilatory prostaglandins (PGs) such as PGD2
and PGE2, resulting in what is commonly referred
to as the “niacin flush” for patients adhering to
niacin therapy, the niacin flush can be intolerable,
leading to the discontinuation of treatment8. Alternate drug delivery methods, including extended
release (ER) niacin, have been reported to reduce
flushing effects9. Despite the improved effects of
ER formulation on niacin-induced flushing, many
patients still present with increased flushing symptoms. An 8 week, double-blind, placebo controlled
study conducted by Paolini et al10 showed that
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Figure 1. Chemical structure of niacin.

compared to control, patients undergoing ERniacin treatment experienced greater flushing
severity throughout the duration of the study with
40% of patients receiving ER-niacin presenting
with moderate or greater flushing severity at least
once a week. Furthermore, a retrospective, cohort
study11 analyzing patient compliance followed the
prescription pattern of 14,386 patients receiving
ER-niacin. The study showed that only 47% of the
patient population reached recommended daily
dosages and that after one year, only < 15% of patients were still receiving ER-niacin therapy. In
another study12 looking at niacin tolerability, it
was shown that 50.8% of patients receiving ERniacin therapy presented with severe or extreme
flushing symptoms. These studies indicate the
need for development of a more tolerable means
of niacin administration.
Biodegradable polymers such as polylactideco-glycolide (PLGA) and, polylactic acid (PLA)
are among the more popular candidates for fabrication of novel drug delivery systems13. PLGA
and PLA are commonly used in the development
of nanoparticle (NP) delivery systems that present
with altered biocompatibility and biodegradation
characteristics14. Polymer based NPs have been
shown to control and prolong the rate of drug release via modulation of NP characteristics such as
hydrophilicity and biodegradation14,15. Alterations
in drug kinetics and release profiles brought forth
by polymer encapsulation have been positively
correlated with reductions in a number of adverse

drug side effects16-18. Despite the documented effectiveness of polymeric NPs and their known capabilities of altering systemic drug exposure, no
formulation studies have been devised in regard
to polymer encapsulated niacin-loaded NPs. The
purpose of this study was to develop a novel, NP
formulation of entrapped niacin, utilizing the
biodegradable polymers PLGA and PLA with the
stabilizer, didodecyldimethylammonium bromide
(DMAB). In this study, NPs were created through
a common emulsion-diffusion-evaporation
process19,20. The resultant particles were characterized for size, zeta potential, and percentage of
niacin entrapment. In vitro NP drug release and
effects on PGE2 levels following niacin exposure
were also evaluated.

Materials and Methods
Materials
Nicotinic acid, DMAB, PLA (MW 85,000160,000 Da), and PLGA (50:50 copolymer compositions; MW 30,000-60,000 Da), were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Ethyl acetate, acetone, and high performance liquid chromatography (HPLC) grade water were purchased from Fischer Scientific Laboratory (Fair Lawn, NJ, USA). Human blood and
PGE2 ELISA kit were obtained from Innovative
Research Inc. (Novi, MI, USA) and Thermo Scientific (Rockford, IL, USA), respectively.
Preparation of PLGA Formulations
Formulation of PLGA based NPs was carried out
using an emulsion-diffusion-evaporation process19.
Organic phase consisting of 50 mg PLGA and 45
mg niacin dissolved in 3 mL ethyl acetate was
added to 6 mL HPLC grade water containing 0.1%,
0.25%, 0.5%, or 1% w/v DMAB stabilizer. Suspensions were probe sonicated for 5 minutes at 20 kHz
to create the primary emulsion and then diluted

Table I. Method for PLGA niacin formulation.

Organic Phase
Aqueous Phase

1

Ingredients

Comments

Amount

PLGA
Ethyl Acetate
Niacin
DMAB
HPLC grade water

Polymer
Primary organic solvent
Hydrophilic drug
Stabilizer
Primary aqueous solvent

50 mg
3 mL
45 mg
Variable1
6 mL

DMAB concentrations varied 0.1, 0.25, 0.5, and 1% w/v with respect to solvent
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Table II. Method for PLA niacin formulation.

Organic Phase
Aqueous Phase

Ingredients

Comments

Amount

PLA
Dichloromethane
Niacin
DMAB
HPLC grade water

Polymer
Primary organic solvent
Hydrophilic drug
Stabilizer
Primary aqueous solvent

50 mg
3 mL
45 mg
Variable1
6 mL

1

DMAB concentrations varied 0.1, 0.25, 0.5, and 1% w/v with respect to solvent

with 25 mL HPLC grade water (Table I). Following
dilution, suspensions were stirred for 2 hours at 750
rpm to ensure organic phase evaporation, then centrifuged at 10,000 g for 5 minutes. After centrifugation, supernatant was collected and characterized.
Formulation of PLA based NPs was carried out using a similar method with dichloromethane as organic solvent (Table II).
NP Characterization
Particle Size, Polydispersity, and Zeta
Potential of Nanoparticles
Formula supernatant samples were used for
characteristic measurements of NP size, polydispersity index (PDI), and zeta potential. All measurements were performed in triplicate. NP size
and PDI were determined by dynamic light scattering using a NICOMP ZLS particle sizer (Particle Sizing Systems, Port Richey, FL, USA).
PDI values range from 0 to 1 with higher values
representing less homogeneous NP size distribution21. Zeta potential was determined using electrophoretic mobility.
Drug Entrapment
Percent drug entrapment was measured by ultraviolet-visible spectroscopy (Eppendorf Biophotometer, Hauppauge, NY, USA). Niacinloaded NP suspensions (100 µL) were added to
acetonitrile (300 µL) and vortex mixed for 15
seconds. After controlling for blank, suspensions
were analyzed at 260 nm. Prior to NP analysis,
niacin stock solution dissolved in HPLC grade
water was used to construct a standard calibration
curve (50,000-2,000,000 ng/mL). Percent drug
entrapment was calculated using an equation presented in a previous publication19.
Morphology
To analyze shape and surface morphology,
formulations were vortex mixed and 2 µL of NP

suspension was placed on a 200 mesh copper
grid coated with Formvar (Electron Microscopy
Sciences, Hatfield, Pennsylvania). Samples were
allowed to dry for 1 hour then examined at 80 kV
by transmission electron microscopy (TEM)
(Tecnai Philips Transmission Electron Microscope; FEI, Hillsboro, OR, USA).
In vitro Release
Measurement of niacin in vitro release was carried out as previously described with slight modification19,22-24. Suspensions containing niacin formulated NPs (2 mL) were placed into 15 mL
Corning centrifuge tubes containing 8 mL phosphate buffer (pH 7) then positioned on a rotating
shaker set at 100 rpm. At varying time points, 2
mL of release medium was removed and replaced
with equal volume of fresh medium. Sample
aliquots were then centrifuged at 1,500 g for 5
minutes and filtered through a 0.2 micron syringe
filter (EMD Millipore, Billerica, MA, USA).
Empty nanoparticle suspensions were used to
control for blank and analysis was carried out using a UV spectrophotometer set at 260 nm.
In vitro Examination of PGE2 Expression
Vascularization effects of niacin are mitigated
by vasodilatory PGs4 such as PGE2. In our study,
in vitro evaluation of PGE 2 release following
niacin exposure was carried out to serve as a
model for niacin-induced flushing25. For evaluation of PGE2 release, 1 mL human blood-citrate
mixture was placed inside a clean glass tube.
Plain niacin or niacin-loaded NP suspensions
were added to human blood (5 mM niacin concentration) and incubated for 1 hour. One portion
of fresh blood-citrate mixture was also incubated
without niacin or NP containing niacin to serve
as control. After 1 hour, samples were centrifuged at 3,000 g for 15 minutes. Supernatant
was collected and PGE 2 concentrations were
evaluated using a PGE 2 ELISA detection kit.
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Results
Effects of DMAB Stabilizer on
Niacin-loaded PLGA-NP Size,
Polydispersity, and Stability
Characterization studies showed a reduction
in particle size with elevated zeta potential using high concentrations of DMAB stabilizer
(Figure 2). Higher NP size was seen in PLGA
formulations using 0.1% w/v DMAB (115.53 ±
5.24 nm) and 0.25% w/v DMAB (104.43 ± 6.04
nm) formulations. NP size was found to be lowest at 0.5% w/v and 1% w/v DMAB (73.03 ±
0.32 nm and 66.70 ± 0.21 nm, respectively)
(Figure 2A). Polydispersity index (PDI) as a
measure of size distribution of NP systems,
showed narrow particle size distribution across
all NP formulations. Formulations of 0.1%
DMAB concentrations showed the lowest homogeneity for size distribution, displaying a
PDI value of 0.15 ± 0.014 (Figure 2B). The
highest level of size homogeneity was seen in
formulations using 0.25% DMAB with a minimum PDI of 0.07 ± 0.02 (Figure 2B). Zeta potential increased above 20 mV for all formulations, with the highest measurements seen in
formulations using 0.25% w/v DMAB (29.52 ±
2.36 mV) and 1% w/v DMAB (42.01 ± 1.62
mV) concentrations (Figure 2C).

Figure 2. The effect of various DMAB concentrations on
niacin-loaded PLGA-NP A) size, B) polydispersity, and C)
zeta potential. Values are expressed as mean ± SD, n = 3.

Samples were analyzed per kit instructions and a
cloud based data analysis software (MyAssays
Ltd, Sussex, England) capable of performing a
four parameter logistic fit was used to generate
the standard curve.
Statistical Analysis
Data are presented as mean ± standard deviation (SD). The unpaired Student’s t-test was used
to analyze cumulative release data for PLGAand PLA-NPs using identical stabilizer concentrations. For NP effects on PGE2 release, oneway ANOVA with post-hoc LSD was used to
compare formulation effects. Statistical significance was set at p < 0.05.
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Effects of DMAB Stabilizer on
Niacin-loaded PLA-NP Size, Polydispersity, and Stability
The use of PLA polymer in formulations resulted in the formation of larger niacin-loaded
NPs than PLGA formulations. The largest particle size was observed using 0.5% DMAB concentrations (212.21 ± 0.56 nm). The lowest average NP size of PLA formulations was achieved
using 0.25% DMAB (130.41 ± 0.68 nm) (Figure
3A). Narrow size distribution was achieved
across all PLA formulated NP systems. Formulations using either 0.5% or 1% DMAB concentrations demonstrated increased system homogeneity as evident by reduced PDI values (0.11 ± 0.01
and 0.11 ± 0.02, respectively). Formulations with
0.1% DMAB showed the lowest level of homogeneity, displaying a PDI value of 0.15 ± 0.01
(Figure 3B). Zeta potential of PLA based NPs
followed a linear increase in relation to stabilizer
concentrations, with a peak zeta potential
achieved using 1% DMAB concentrations (27.96
± 0.18 mV) (Figure 3C).
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Effects of DMAB stabilizer on NP
Entrapment
All PLGA formulations achieved greater than
60% drug entrapment (Table III). The lowest
amount and percent of drug entrapped was seen
in formulations using 0.5% DMAB (28.42 ± 0.01
mg and 63.15 ± 0.01%, respectively). Peak
amount (31.09 ± 0.13 mg) and percent drug entrapment (69.09 ± 0.29%) was achieved using
0.25% w/v DMAB (Table III). No association
between amount and percent of drug entrapment
was determined in regards to increasing or decreasing stabilizer concentrations.
All PLA formulations achieved greater than
50% drug entrapment (Table IV). Peak NP drug
amount and percent entrapment were achieved
using 0.25% w/v DMAB concentrations (31.33 ±

Table III. Effects of DMAB concentrations on PLGA-NP
niacin entrapment.
DMAB
(% w/v)
0.1
0.25
0.5
1

Amount
entrapped (mg)

% EE

29.72 ± 0.35
31.09 ± 0.13
28.42 ± 0.01
30.17 ± 0.13

66.03 ± 0.77
69.09 ± 0.29
63.15 ± 0.01
67.05 ± 0.29

All values reported as mean ± SD (n = 3). Amount entrapped per 45 mg niacin. EE is the entrapment efficiency.

0.02 mg and 69.63 ± 0.03%, respectively); while
the lowest drug amount and percent entrapment
were found in formulations using 0.1% DMAB
concentrations (26.27 ± 0.07 mg and 58.38 ±
0.15%, respectively). Similar to PLGA-NPs,
there was no noted relationship between stabilizer concentration and drug entrapment in PLA
formulated NPs.
Shape and Surface Morphology of
Niacin-loaded PLGA-NPs
Morphological features of PLGA-NPs showed
well defined, round, separated, spherical particles
with smooth surfaces (Figure 4). PLA formulated
NPs also presented with well separated, smooth
particles typified by a round spherical shape
(Figure 5). For both PLGA and PLA formulations, TEM size confirmation was in agreement
with similar size parameters obtain during characterization studies performed with the zeta sizer.
In vitro Niacin Release
In vitro release studies were performed on
both PLGA and PLA niacin-loaded NPs. Only
DMAB stabilizer concentrations of 0.25% and
1% w/v were chosen based on their degree of

Table IV. Effects of DMAB concentrations on PLA-NP
niacin entrapment.
DMAB
(% w/v)
0.1
0.25
0.5
1
Figure 3. The effect of various DMAB concentrations on
niacin-loaded PLA-NP A) size, B) polydispersity, and C) zeta potential. Values are expressed as mean ± SD, n = 3.

Amount
entrapped (mg)

% EE

26.27 ± 0.07
31.33 ± 0.02
28.85 ± 0.07
26.83 ± 0.02

58.38 ± 0.15
69.63 ± 0.03
64.35 ± 0.16
59.62 ± 0.03

All values reported as mean ± SD (n = 3). Amount entrapped per 45 mg niacin. EE is the entrapment efficiency.
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GA- and PLA-NP reached a cumulative release
of 67.84 ± 0.08 % and 73.54 ± 0.68%, respectively (Figure 6) (p < 0.01). Initial release of
niacin was significantly lower in the 1% w/v
DMAB PLGA-NP formulated group (18.88 ±
0.03%) in comparison to the 1% w/v DMAB
PLA formulated group (21.11 ± 0.03 %) (p <
0.01). After 48 hours, 1% w/v DMAB formulated PLGA-NPs had a total cumulative release of
63.47 ± 0.14%, which was significantly lower
than the total release of 81.11 ± 0.11% observed
in the 1% w/v DMAB PLA formulated group
(Figure 7) (p < 0.01).

Figure 4. Morphological analysis of niacin-loaded PLGANPs. Transmission electron microscopy image of niacinloaded PLGA-NPs formulated with 0.25% DMAB stabilizer
(A). Transmission electron microscopy image of niacinloaded PLGA-NPs formulated with 1% DMAB stabilizer (B).

stability, particle size, and percent of drug entrapped. Comparison of percent drug release
showed statistical significance between both
PLGA- and PLA based NPs using 0.25% w/v or
1% w/v DMAB. At each specific time point,
PLGA based NPs formulated at both 0.25% and
1% DMAB demonstrated a reduced rate of release when compared to PLA based NPs (Figure
6 and Figure 7). The initial release (0.5 hours)
for PLGA-NPs formulated with 0.25% w/v
DMAB reached 17.81 ± 0.02%, while 0.25%
w/v DMAB formulated PLA-NPs showed an
initial release of 20.53 ± 0.04% (p < 0.01). After 48 hours, 0.25% w/v DMAB formulated PL3982

Figure 5. Morphological analysis of niacin-loaded PLANPs. Transmission electron microscopy image of niacinloaded PLA-NPs formulated with 0.25% DMAB stabilizer
(A). Transmission electron microscopy image of niacinloaded PLA-NPs formulated with 1% DMAB stabilizer (B).
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Figure 6. PLGA and PLA niacin-loaded NP in vitro drug release study with 0.25% DMAB stabilizer concentration. In vitro release profile of niacin in phosphate buffer (pH 7) from 0.25% DMAB formulated NPs (mean ± SD, n = 3, *p < 0.05).

NP in vitro Effects on Prostaglandin
Release
To measure in vitro effects of niacin-loaded
NP formulations on prostaglandin levels, experiments evaluating extent of PGE2 release were
carried out using whole human blood samples.
One-way ANOVA demonstrated marginal differences among treatment groups (p = 0.06).
When compared to control (234.84 ± 73.01
pg/mL), PGE2 expression assessed 1 hour after
exposure of plain niacin formula showed a significant increase in PGE2 blood concentrations
(804.78 ± 95.16 pg/mL) (p = 0.01). All niacinloaded PLGA-NP formulations experienced no
significant increase in PGE 2 concentrations
when compared to control. When compared to
plain niacin, the use of 0.25% (389.09 ± 13.93
pg/mL, p = 0.03), 0.5% (291.08 ± 325.93
pg/mL, p = 0.01), and 1% (415.99 ± 4.04
pg/mL, p = 0.03) DMAB formulated niacinloaded PLGA-NPs showed a significant reduction in PGE2 blood concentrations (Figure 8).
The use of niacin-loaded PLA-NP formulations
showed no significant difference in PGE2 ex-

pression when compared to plain niacin formula (data not shown).

Discussion
Niacin has been used for decades as a method
to effectively treat dyslipidemia and associated
cardiovascular diseases. To date, it remains one
of the few available drugs shown to favorably affect multiple lipoprotein parameters3. Adverse
flushing side effects associated with high dose
niacin consumption has restricted the use of this
highly valuable, lipid regulating drug. To help
mediate vasodilatory effects of niacin, extended
and prolonged oral delivery systems have been
developed26. These unique delivery systems have
shown improvements in the control of niacin-induced vasodilation, yet perpetuation of the niacin
flush still persists as one of the more commonly
reported side effects10,27. Over the years, polymeric NPs have been effectively used in the development of controlled drug delivery systems28.
Highly biodegradable polymers such as PLGA
3983
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Figure 7. PLGA and PLA niacin-loaded NP in vitro drug release study with 1% DMAB stabilizer concentration. In vitro release
profile of niacin in phosphate buffer (pH 7) from 1% DMAB formulated NPs (mean ± SD, n = 3, *p < 0.05).

and PLA have been approved for human use by
the Food and Drug Administration29. The application of these polymeric materials has ranged
from development of artificial cartilage and skin,
to the creation of NP delivery systems used in the
delivery of various bioactive compounds29. PLGA and PLA polymers have been commonly
used for the development of sustained drug delivery systems 13,30. Furthermore, polymeric NPs
have been shown to control drug release by altering the rate of NP biodegradation and matrix erosion, leading to reduced or sustained systemic
drug delivery over a prolonged period of time.
Due to altered drug release characteristics of
polymeric NP systems, we hypothesized that use
of polymer encapsulated niacin NP systems
could reduce flushing effects associated with
niacin consumption. Therefore, the primary objective of our research was the development and
optimization of a novel, reformulated, polymeric
NP delivery system for niacin that could minimize associated flushing effects and function as
an effective replacement for traditional oral
niacin delivery.
3984

Particle size is an important characteristic for
optimization of effective NP systems, as size can
influence cellular uptake, tissue diffusion,
bioavailability, and/or rate of degradation 31.
Many factors, including the type of polymer
used as well as addition of effective stabilizers,
can affect particle size. In our study, we found
that PLGA-NPs demonstrated a reduction of
particle size in relation to DMAB concentrations. As DMAB concentrations increased, particle size decreased with the smallest average particle size seen at 1% w/v DMAB concentrations
(Figure 2A). Consequently, use of PLA in NP
formulations showed no association between
particle size and DMAB concentrations (Figure
3A). A possible explanation for these observations could be based on polymer molecular
weight31,32. The PLGA polymers represented in
our study have a molecular weight of 30,00060,000 Da, while the molecular weight of its
PLA counterpart were 85,000-160,000 Da. Alterations in polymer type during the formulation
process resulted in a 55,000-100,000 Da difference in molecular weight. It is possible that this

Effect of nanoparticle formulation on niacin-induced flushing

shift in molecular weight resulted in an increase
in polymer suspension viscosity32, which would
result in a net reduction in particle dispersion
following physical agitation during the formulation process. Reduced efficiency of emulsion
droplet dispersion utilizing the same agitation
parameters would result in an increase in NP
size.
Zeta potential represents a measure of system
stability based on net charge and systemic attraction or repulsion of developed NPs 33. In our
study, NPs developed using both PLGA and PLA
polymers demonstrated high, positively charged,
zeta potential values (Figure 2C and Figure 3C,
respectively). DMAB is a highly cationic stabilizer used in our drug formulation process19,34.
Previous studies have shown that inclusion of
DMAB into formulation parameters resulted in a
net increase in charged NP systems35,36. PLA formulated NPs showed a concentration dependent
increase in zeta potential in relation to DMAB
concentration, indicating that as stabilizer concentration increased, inclusion of stabilizer into
NP shell can increase as well. Overall, in both
PLGA and PLA formulated NPs, the use of
DMAB resulted in a net increase of cationic
DMAB inclusion within the NP surface, thus giv-

ing highly positive surface charges to our newly
formulated NP systems.
NP drug entrapment did not present a consistent pattern. For both PLGA and PLA formulated
NPs, drug entrapment was highest utilizing
0.25% w/v DMAB concentration. The lowest
level of drug entrapment was seen in PLGA and
PLA formulations using 0.5% and 0.1%, respectively (Table III and Table IV). The process of
drug entrapment is highly dependent on solvent
diffusion and a drug’s partition co-efficient31. In
comparison to PLGA entrapment, it is possible
that increased solvent viscosity of the higher
molecular weight PLA led to an overall reduction
in drug entrapment via reduced solvent diffusion
into the aqueous media. The rate of solvent diffusion may act to slow the degree of polymer precipitation, effectively increasing the time allowed
for drug partition into the aqueous phase, leading
to a net reduction of drug entrapment.
Morphological examination of 1% and 0.25%
formulations via TEM showed NPs that were
mostly spherical in shape, with distinct and well
defined borders that displayed moderate particle
separation (Figure 4 and Figure 5). These visual
verifications were consistent with our characteristic studies performed with the zeta sizer. TEM

Figure 8. Effects of niacin-loaded PLGA-NP formulations on PGE2 release (mean ± SD, n = 2, *p < 0.05, significantly different
from control, #p < 0.05, significantly different from plain niacin formulation).
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scale measurement of NPs where also in range
with our particle size observations. It is important to note that particles with a larger charge undergo an increasing degree of repulsion in comparison to lower charged particles37. The degree
of repulsion effectively functions to mitigate particle aggregation and increase system separation
and stability, suggesting the use of DMAB for
stable formulation of both PLGA and PLA based
niacin-loaded NPs.
Niacin release from PLGA- and PLA-NPs
demonstrated differing results in relation to polymer type. When formulated with 0.25% or 1%
DMAB concentrations, initial drug release were
significantly reduced in the PLGA group in comparison to PLA formulated NPs. Furthermore,
overall cumulative drug release was significantly
lower in PLGA formulated NPs (Figure 6 and
Figure 7). Past studies have suggested correlation
between drug release and drug entrapment 38.
When high concentrations of drug are entrapped
within a NP shell, crystallization of the drug can
occur. This process can result in increased crystallized drug formation within the inner core of
the NP shell. In turn, crystallized drug should
dissolve, diffuse, and release more slowly than an
equally dispersed drug39. When comparing the
amount of niacin released from PLGA- and PLANPs against the degree of drug entrapment, it can
be speculated that niacin release from 0.25% and
1% DMAB formulated PLGA-NPs undergoes
significant reduction, possibly as a result of an
increased concentration of crystallized drug entrapped within the NP shell. Furthermore, the
higher burst release observed for PLA formulations can be attributed to reduced particle size, a
short diffusion path, and/or compositional matrices interactions of the formulation40,41. All formulations showed adequate reduction in particle
size, with the largest particle size obtained in
PLA formulation at 1% DMAB (159.53 ± 27.96
nm) (Figure 2 and Figure 3). However, this does
not explain why PLGA formulations of a much
smaller size yielded a significant reduction in
drug release following 0.25% and 1% DMAB
formulations. It is possible that formulations with
PLA polymers could result in a shortened diffusion path through the polymer matrix that allow
higher amounts of niacin to leak out of the NP
shell during initial entrapment measurements40,41.
Furthermore, altered matrices interactions of differing NP formulations may increase drug adhesion to the NP wall leading to delayed or reduced
drug release42.
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ELISA assay of in vitro experiments using human blood detected significant increases in concentrations of PGE2 in samples treated with plain
niacin, when compared to control (non-treated
blood samples) (p = 0.01). Increased in vitro PG
release in response to niacin exposure has been
shown to occur below 5 mM concentrations25.
The use of identical concentrations of niacin (5
mM) loaded into PLGA-NPs demonstrated reductive effects in PGE2 release when compared
to plain niacin (Figure 8). Niacin-loaded PLGANPs showed significant reductions in PGE2 release when formulated at 0.25%, 0.5%, and 1%
DMAB concentrations. Enhanced NP characteristics such as size and zeta potential correlated
favorably with noted reductions in PGE2 release.
All formulations that demonstrated a significance
reduction in PGE2 presented with more favorable
NP characteristics than the non-significant 0.1%
w/v DMAB formulation. PLGA formulations
that produced a significant net reduction in PGE2
release presented with particles sizes of 104 nm
or less and zeta potential at or above 25 mV;
while the non-significant formulation (0.1% w/v
DMAB) achieved a particle size and zeta potential of 115 nm and 23 mV, respectively (Figure
2). No formulations using PLA polymers showed
any significant reductions in PGE2 concentrations
when compared to plain niacin (data not shown).
It is worth noting that characteristic studies performed on niacin-loaded PLA-NPs showed larger
NP size parameters and reduced zeta potential
when compared to PLGA-NP formulations (Figure 3). Taking into account changes seen in the
PGE2 expression between polymer formulations,
a logical assumption can be made that the role of
size and zeta potential as a measure of system
stability plays a vital role in the control of niacininduced PGE2 expression. Furthermore, the elucidation of release patterns seen with both formulations indicates that PLGA formulated niacinloaded NPs function to reduce the rate and extent
of niacin exposure, thus potentially leading to a
net reductive effect in PGE2 release.

Conclusions
This study used a simplified solvent diffusion
evaporation technique to formulated PLGA and
PLA niacin-loaded NPs. The results of our characteristic work demonstrated effective formulation
of small, highly stable, niacin entrapped NPs for
both polymer types. In vitro release experiments
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showed significantly reduced niacin release of PLGA formulated NPs in comparison to PLA formulated NPs. Furthermore, in vitro studies using
whole human blood demonstrated niacin-loaded
PLGA-NP effectiveness at significantly reducing
PGE2 release in comparison to plain niacin treatment. Effects noted in our in vitro studies may indicate the use of niacin-loaded PLGA-NP for controlled release of niacin. A conclusion can be
made that the altered state of niacin release seen in
PLGA formulations effectively reduced PGE2 release. Therefore, our results may indicate the use
of PLGA formulated niacin-loaded NPs for the reduction of PG-induced niacin flushing. Further investigations are warranted to elucidate optimum
niacin NP formulation and its effects on niacin induce vasodilation.
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